Linda Z. Swartz 

Partner – New York
T.+1 212 504 6062
linda.swartz@cwt.com
200 Liberty Street
New York , NY 10281 V-CARD

Linda Swartz, the chair of Cadwalader's Tax Group and a member of the firm's Management Committee, focuses her practice on structuring complex global mergers and acquisitions, spin-offs, joint ventures, and restructurings, and on foreign tax planning strategies. She also has considerable experience advising clients on financings, derivative transactions and executive compensation issues.

Awards and Honors

Linda is consistently recognized by industry publications and independent commentators as one of the leading corporate tax lawyers in the country. She has been described by Chambers USA as “acclaimed for her vast reservoir of practical knowledge of the U.S. tax code” and “an expert on the law of today but cognizant of where the law might go in the future, allowing clients to make decisions which last for the next ten years.” She was recently recognized as “2017 Foreign Tax Planning Lawyer of the Year” by Finance Monthly, and Dow Jones, reporting on Procter & Gamble’s Reverse Morris Trust transaction with Coty, noted that “it isn’t often you see a tax adviser credited on a deal, but that’s exactly what happened for Cadwalader, Wickersham & Taft in P&G’s complicated $12.5 billion unloading of its beauty business to Coty.” Additional recognition includes: 

  • Tax Directors Handbook – named as one of the 16 Top U.S. Tax Advisors
  • Chambers USA – Selected as a Leading New York Tax Lawyer
  • The Legal 500 – Selected as a Leading Lawyer
  • International Tax Review – Selected as a Leader in U.S. and International Tax
  • International Who's Who – Selected as a Leading Corporate Tax Lawyer
  • Euromoney Publications – Selected as a Leading U.S. Tax Lawyer
  • Expert Guides – Selected as a Leading U.S. Tax Lawyer and Woman in Business Law
  • Finance Monthly – 2018 Foreign Tax Planning Law Firm of the Year (USA)
  • Guide to the World's Leading Women in Business Law: Tax
  • ICFM – Selected as one of the Top 500 Global Lawyers
  • Lawyers Worldwide Awards Magazine – Innovative Lawyers 2017
  • Super Lawyers – Selected as one of the Top 50 Women Lawyers in New York City
  • Avenue Legal Elite – Selected as one of New York City's Top Women Attorneys
  • U.S. News Best Lawyers “Best Law Firms” – Selected as a Leading Lawyer and National Tier 1 Tax Law Firm
  • Who’s Who Legal: Corporate Tax
  • Who's Who in the World
  • Who's Who of American Women
  • Who's Who in American Law
  • Martindale Hubbell (AV-rated)

Articles, Publications and Speaking Engagements

Linda frequently speaks and writes on transactional tax issues. Her recent articles include:

She also authors the chapters on Debt Exchanges in Collier on Bankruptcy Taxation (Matthew Bender) and Securities Lending Transactions in Taxation of Financial Institutions (Clark Boardman Callaghan). In addition to writing, she speaks on a broad range of topics, including each year at the PLI conferences on corporate, partnership, and real estate tax issues.

Professional Affiliations

  • Executive Committee Member, New York State Bar Association Tax Section
  • Former Chair, Tax-Free Reorganizations, Corporations Bankruptcy, Consolidated Returns, Real Property, and Tax Accounting and Basis Committees, New York State Bar Association Tax Section

Education

  • University of Pennsylvania Law School
    J.D. 1987
  • Bucknell University
    B.A., magna cum laude, Phi Beta Kappa 1984

Representative Experience and Clients

Most recently, Linda played a leading role on behalf of her clients in the following high-profile transactions, representing:

  • The Medicines Company in its agreement to sell its infectious disease business to Melinta Therapeutics, Inc. for $270 million and royalty payments on net sales of the pharmaceutical products sold to Melinta in the transaction.
  • Procter & Gamble Co. in the split-off and tax-free merger of its Specialty Beauty business with Coty Inc. in a Reverse Morris Trust transaction.
  • Salix Pharmaceuticals, Ltd. in its $15.6 billion acquisition by Valeant Pharmaceuticals International, Inc.
  • The Medicines Company in its agreement to divest three of its marketed cardiovascular products and related assets to Chiesi Farmaceutici S.p.A., for up to $792 million.
  • Procter & Gamble Co. in the tax-free exchange of its Duracell business for P&G shares held by Berkshire Hathaway.
  • Sompo International in its agreement to purchase the operating subsidiaries of Lexon Surety Group LLC. 
  • New Mexico Health Connections in the sale of its commercial health insurance business to Evolent Health, Inc.
  • The Pasha Group in its acquisition of the Hawaii trade-lane business of Horizon Lines.
  • Salix Pharmaceuticals in its terminated combination with Cosmo Technologies, a subsidiary of Cosmo Pharmaceuticals, to form Salix Pharmaceuticals, plc.
  • Acorda Therapeutics in its acquisition of Civitas Therapeutics.
  • Élan Corporation, PLC in its tax-free distribution of its stock of Prothena.
  • Procter & Gamble Co. in its sale of the Pringles Group to Kellogg.
  • Procter & Gamble Co. in the proposed tax-free distribution and acquisition of its snack business by Diamond Foods Inc.
  • JPMorgan in Dell Inc.'s acquisition by Michael Dell and Silver Lake Partners.
  • Vertis Holdings in connection with its section 363 sale to Quad/Graphics.
  • Quest Software, Inc. Chairman and CEO Vincent Smith in the $2.4 billion sale of Quest Software to Dell Inc.
  • Pfizer, Inc. in the sale of its Capsugel business to Kohlberg Kravis Roberts.
  • Dayton Power and Light in its sale to AES Corporation.
  • Pfizer, Inc. in its acquisition of King Pharmaceuticals, Inc.
  • Icahn Global Enterprises as secured lender in the Blockbuster chapter 11 cases.
  • United States Treasury Department in restructuring CIT.
  • Pfizer, Inc. in its acquisition of the Wyeth Corporation.
  • U.S. Department of Treasury counsel to the Presidential Task Force on the Auto Industry, including advising on the bankruptcy filings of General Motors and Chrysler.
  • Procter & Gamble Co. in the tax-free distribution and immediate acquisition of its Folgers Coffee business by the J.M. Smucker Company.
  • LyondellBasell Chemical Company as lead debtor's counsel in its chapter 11 case.
  • Towers Watson & Co., in its acquisitions of Acclaris and Extend Health Inc.
  • Xerium Technologies, Inc. in its prepackaged chapter 11 cases.
  • Caribbean Petroleum Corporation in its chapter 11 cases.
  • Auto Task Force on General Motors' exposure to Delphi Corporation.
  • Official Committee of Unsecured Creditors of Truvo USA LLC and its affiliates.
  • JPMorgan Chase Bank, N.A. in the Centro Properties restructuring.
  • JPMorgan Chase Bank, N.A. in the Stations Casino chapter 11 cases.
  • Northwest Airlines Corporation in its chapter 11 cases.
  • Xstrata in the sale of its aluminum business to Apollo Management.
  • CVC Capital Partners Group on its proposed acquisition of Barclays' iShares unit.
  • RGIS Holdings LLC in connection with its acquisition by The Blackstone Group.
  • Pfizer Inc. in the sale of its consumer healthcare business to Johnson & Johnson.
  • St. Vincent's Catholic Medical Centers in its chapter 11 reorganization case.
  • Procter & Gamble Co. in its acquisition of The Gillette Co.
  • Pfizer Inc. in its acquisition of Pharmacia, Inc.
  • Storage Technology Corporation in its acquisition by Sun Microsystems.
  • The Quaker Oats Company in its acquisition by PepsiCo, Inc.
  • Pfizer Inc. in its hostile takeover of Warner-Lambert Co.

She has also represented Agilent Technologies, The Boeing Company, Bristol-Meyers Squibb, Brunswick Corporation, CBS, Conseco, Del Laboratories, Dreamworks, Dow Jones, ITT Corporation, Mack-Cali, McKesson, Olin Corporation, Palm Inc., TIAA-CREF, Time Warner, Toys ‘R' Us, US Industries and each major investment bank.

NEWS

News Releases

view more »

Recent Press

view more »

RESOURCES

Clients & Friends Memos

view more »
Linda Z. Swartz 

Admissions

  • New York

Education

  • University of Pennsylvania Law School
    J.D., 1987
  • Bucknell University
    B.A., 1984, magna cum laude; Phi Beta Kappa

CadwaladerSpotlight

October 4: CREFC CRE CLO Conference | New York City

Cadwalader partners Stuart Goldstein and Jeffrey Rotblat will speak at this key industry event.

Cadwalader's research and intelligence platform provides analysis on changes in U.S. financial regulation. Subscribers receive a daily newsletter interpreting new laws, rules and enforcement actions that impact financial institutions.